David Langenau

Model developed by HSCI researchers enables visualization of drug response The goal of personalized cancer therapy is to know which drugs will work on a patient’s specific tumor before treatment starts. In a step toward this goal, Harvard Stem Cell...

Annual symposium drives innovative research between CIRM-HSCI scientists The organizers of this year’s Harvard Stem Cell Institute/ California Institute for Regenerative Medicine Junior Faculty Symposium knew that it was time to rebrand. The 40 regulars...

Funds will help support pediatric leukemia work led by HSCI’s David Langenau, PhD A Palmetto Bay, Florida, private school transformed its annual fishing tournament into a fundraiser for childhood cancer research at the Harvard Stem Cell Institute (HSCI)...

Finding in zebrafish may be clinically relevant for humans To identify the mutations that generated the most relapse-prone leukemia, the researchers competed single cancer cells against each other within a zebrafish. (Credit: Jessica Blackburn...

Rhabdomyosarcoma is a rare childhood cancer that arises in muscle stem cells. Between 250-350 cases are treated each year. The disease most commonly begins as a noticeable swelling in the arms, legs, head, neck, or groin, and is treated by surgical...